DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionize the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC). This innovative study focuses on patients who have recently started or switched to lorlatinib therapy, a targeted drug designed to combat this specific type of lung cancer.
Understanding the Trial’s Objectives
As explained by Dr. Malinda Itchins, “when someone has a type of lung cancer that is ALK-positive, they often take inhibitor drugs directed to the ALK target to help treat it. But over time, the cancer can become resistant to this medicine. Right now, doctors don’t have a reliable way to predict when this might happen or how to adjust treatment based on each person’s specific situation.”
DYNAMALK aims to address this critical challenge. By analysing comprehensive genomic profiles, including those derived from circulating tumor DNA (ctDNA) – a “liquid biopsy” obtained from blood samples – researchers hope to:
- Predict resistance: Identify early signs of treatment resistance, allowing for timely adjustments to therapy.
- Guide treatment decisions: Personalise treatment plans based on individual genetic profiles.
- Improve outcomes: Ultimately, enhance the lives of patients with ALK+ NSCLC by improving treatment effectiveness and potentially extending survival.
Participating in DYNAMALK
Participation in DYNAMALK is open to eligible patients. If you believe you may qualify, please contact the study team to discuss your options:
Streamlining Participation
Dr. Itchins emphasises the importance of seamless patient enrollment:
When recruiting to rare cancer trials every single patient that misses the opportunity can make or break the study. Particularly in the patients commencing treatment for the first time, things can be hectic, and additional participation in a laboratory clinical trial might be just the thing that is missed. The study team can make the kits of comprehensive genomic profiling available at your site now to aid in collection of the important baseline samples prior to treatment commencement.
Community Engagement and Fundraising
The success of DYNAMALK is not solely dependent on scientific research. The unwavering support of the ALK+ lung cancer community has been instrumental. Lisa Briggs, inspired by the trial’s potential, spearheaded fundraising efforts among fellow patients, raising over $100,000.
Natalie Dubs, a lung cancer survivor celebrating ten years of life, shared her inspiring story:
“Ten years ago, I was diagnosed with Stage 4 ALK+ lung cancer. Today, I’m celebrating a decade of living life to the fullest, thanks to incredible advancements in medical research, my husband’s and family support and my oncologist forefront knowledge in lung cancer treatments. I’ve travelled the world, bought and renovated a home, and even welcomed a furry friend named Taicho into my life. While managing the disease, I haven’t let it stop me from pursuing my dreams and continuing working.”
Natalie’s commitment to raising over $16,000 for DYNAMALK exemplifies the incredible spirit of the lung cancer community.
Acknowledgments
The DYNAMALK research project is grateful for the generous support of Lung Foundation Australia and Rare Cancers Australia. Their contributions are vital in advancing this crucial research and improving the lives of patients with ALK+ lung cancer.
Support DYNAMALK
You can contribute to the success of this vital research by making a donation to support the DYNAMALK clinical trial. Your generosity will directly impact the lives of patients with ALK+ lung cancer.
